Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Incyte Corporation
  6. Ratings
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 78.66, which offers good timing for buyers.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The company's enterprise value to sales, at 5.7 times its current sales, is high.
  • The firm trades with high earnings multiples: 42.15 times its 2021 earnings per share.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 92.07 USD
Ratings chart
Sector Other Biotechnology & Medical Research
1st jan.Capitalisation (M$)Investor Rating
INCYTE CORPORATION-4.31%18 170
MODERNA, INC.54.48%64 799
LONZA GROUP AG-0.81%46 408
IQVIA HOLDINGS INC.30.62%44 856
CELLTRION, INC.-24.65%32 736
SEAGEN INC.-15.78%26 768
CUREVAC N.V.35.67%21 497
HANGZHOU TIGERMED CONSULTIN..-3.25%20 549
PHARMARON BEIJING CO., LTD.42.02%20 456
CHARLES RIVER LABORATORIES ..28.48%16 537
PPD, INC.34.78%16 187
ALNYLAM PHARMACEUTICALS, IN..4.41%15 951
BIO-TECHNE CORPORATION26.40%15 610
ICON PUBLIC LIMITED COMPANY17.55%12 116
PRA HEALTH SCIENCES, INC.37.39%11 167
QIAGEN N.V.-11.49%10 685
More Results
Financials (USD)
Sales 2021 2 831 M - -
Net income 2021 450 M - -
Net cash 2021 2 027 M - -
P/E ratio 2021 42,2x
Yield 2021 -
Capitalization 18 170 M 18 170 M -
EV / Sales 2021 5,70x
EV / Sales 2022 4,42x
Nbr of Employees 1 773
Free-Float 98,8%
Upcoming event on INCYTE CORPORATION
Surperformance Ratings©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes